tumor necrosis factor (ligand) superfamily, member 4
| GO Term | Evidence Code | PMID |
|---|---|---|
| negative regulation of transcription by RNA polymerase II |
|
|
| blood vessel development |
|
|
| negative regulation of cytokine production |
|
|
| positive regulation of cytokine production |
|
|
| defense response to nematode |
|
| GO Term | Evidence Code | PMID |
|---|---|---|
| extracellular region |
|
|
| extracellular region |
|
|
| extracellular region |
|
|
| obsolete extracellular space |
|
|
| cell surface |
|
| GO Term | Evidence Code | PMID |
|---|---|---|
| cytokine activity |
|
|
| tumor necrosis factor receptor binding |
|
|
| tumor necrosis factor receptor binding |
|
|
| protein binding |
|
|
| tumor necrosis factor receptor superfamily binding |
|
| InterPro |
|---|
| Tumor necrosis factor ligand superfamily member 4 |
| Tumour necrosis factor-like domain superfamily |
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:14557 | primary pulmonary hypertension | |
| DOID:9744 | type 1 diabetes mellitus |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.5.0
Last updated: April 6, 2026